-
Giannis suitors make deals as NBA trade deadline nears
-
Carrick stresses significance of Munich air disaster to Man Utd history
-
Record January window for transfers despite drop in spending
-
'Burned inside their houses': Nigerians recount horror of massacre
-
Iran, US prepare for Oman talks after deadly protest crackdown
-
Winter Olympics opening ceremony nears as virus disrupts ice hockey
-
Mining giant Rio Tinto abandons Glencore merger bid
-
Davos forum opens probe into CEO Brende's Epstein links
-
ECB warns of stronger euro impact, holds rates
-
Famine spreading in Sudan's Darfur, warn UN-backed experts
-
Lights back on in eastern Cuba after widespread blackout
-
Russia, US agree to resume military contacts at Ukraine talks
-
Greece aims to cut queues at ancient sites with new portal
-
No time frame to get Palmer in 'perfect' shape - Rosenior
-
Stocks fall as tech valuation fears stoke volatility
-
US Olympic body backs LA28 leadership amid Wasserman scandal
-
Gnabry extends Bayern Munich deal until 2028
-
England captain Stokes suffers facial injury after being hit by ball
-
Italy captain Lamaro amongst trio set for 50th caps against Scotland
-
Piastri plays down McLaren rivalry with champion Norris
-
ECB holds interest rates as strong euro causes jitters
-
Spain, Portugal face floods and chaos after deadly new storm
-
EU close to sealing trade deal with Australia
-
German Cup final to stay in Berlin until 2030
-
What does Iran want from talks with the US?
-
Taming the lion: Olympians take on Bormio's terrifying Stelvio piste
-
Wind turbine maker Vestas sees record revenue in 2025
-
Italy's Casse tops second Olympic downhill training
-
Anti-doping boss 'uncomfortable' with Valieva's coach at Olympics
-
Bitcoin under $70,000 for first time since Trump's election
-
'I am sorry,' embattled UK PM tells Epstein victims
-
England's Brook predicts record 300-plus scores at T20 World Cup
-
Ukraine, Russia swap prisoners, US says 'work remains' to end war
-
Wales' Rees-Zammit at full-back for Six Nations return against England
-
Sad horses and Draco Malfoy: China's unexpected Lunar New Year trends
-
Hong Kong students dissolve pro-democracy group under 'severe' pressure
-
Germany claws back 59 mn euros from Amazon over price controls
-
Germany claws back 70 mn euros from Amazon over price controls
-
VW and Stellantis urge help to keep carmaking in Europe
-
Stock markets drop amid tech concerns before rate calls
-
BBVA posts record profit after failed Sabadell takeover
-
UN human rights agency in 'survival mode': chief
-
Greenpeace slams fossil fuel sponsors for Winter Olympics
-
Greenpeace slams fossel fuel sponsors for Winter Olympics
-
Kinghorn, Van der Merwe dropped by Scotland for Six Nations opener
-
Russia says thwarted smuggling of giant meteorite to UK
-
Salt war heats up in ice-glazed Berlin
-
Liverpool in 'good place' for years to come, says Slot
-
Heathrow still Europe's busiest airport, but Istanbul gaining fast
-
Highest storm alert lifted in Spain, one woman missing
China approves first domestic mRNA vaccine for Covid-19
China has approved its first locally developed messenger RNA (mRNA) vaccine against Covid-19, its manufacturer said Wednesday, months after the relaxation of strict Covid-zero regulations sparked a surge in cases.
The vaccine, developed by CSPC Pharmaceutical Group Ltd, has been approved for "emergency use" by Beijing's health regulator, the company said in a statement.
It showed high efficacy in a trial in which it was used as a booster shot for people who have been given other types of vaccines, the company added, without offering further details.
mRNA vaccines are considered among the most effective in reducing severe infections and deaths.
While traditional vaccines use a weakened or inactivated germ to prepare the body for a future attack from the real virus, mRNA deploys snippets of genetic material that carry instructions showing the body's cells how to produce a protein -- in this case, the spike protein on the coronavirus that causes Covid.
The body's immune system then triggers antibodies to fight off that spike protein, making it ready for when the real coronavirus comes knocking.
Beijing has refused to greenlight mRNA-based vaccines from foreign firms Pfizer-BioNTech and Moderna for public use.
Its vaccination shortfall was widely believed to have led to more severe infections and deaths after lockdowns and mandatory quarantine rules were suddenly dropped in December.
Other Chinese drugmakers including CanSino have previously said they were developing mRNA-based shots to help the country bridge its immunisation gap.
J.Fankhauser--BTB